

IN THE CLAIMS

Amend the claims as follows.

1. (Currently Amended) A gene transfer vector which contains
 - a) a transgene consisting of a ~~therapeutic gene or a suicide gene~~ and
 - b) a nucleic acid sequence coding for a human CD34 surface marker or a cytoplasmically completely or partially deleted variant ~~fragment of the same or a variant~~ of the same, wherein
said surface marker or ~~fragment or variant~~ is expressible as a surface marker and is identifiable by an antibody against CD34.

2. (Currently Amended) The vector according to claim 1, wherein the nucleic acid sequence codes for a surface marker comprising SEQ ID NO:2, 4 or 6, ~~or for a fragment of SEQ ID NO:2, 4 or 6, or for a variant of SEQ ID NO:2, 4 or 6, said surface marker or fragment or variant being expressible as a surface marker and being identifiable by an antibody against CD34.~~

3. (Currently Amended) The vector according to Claim 1, wherein the nucleic acid sequence comprises SEQ ID NO: 1, 3 or 5, ~~or a fragment of SEQ ID NO: 1, 3 or 5, or a variant of SEQ ID NO: 1, 3 or 5, said fragment or variant coding for an amino acid sequence which is expressible as a surface marker and is identifiable by an antibody against CD34.~~

4. (Previously Presented) The vector according to Claim 1, wherein the vector is a retroviral vector.

5. (Previously Presented) The vector according to Claim 1, further comprising a second nucleic acid sequence coding for a second surface marker.

6. (Original) A vector with the accession no. DSM 13396.

7. (Currently Amended) A vector comprising a nucleic acid sequence coding for an amino acid sequence comprising SEQ ID NO:6, ~~or for a fragment of SEQ ID NO:6, or for a variant of SEQ ID NO:6, wherein said fragment or variant is identifiable by an antibody against CD34.~~

8. (Currently Amended) A vector comprising a nucleic acid sequence-comprising SEQ ID NO:5, ~~or a fragment of SEQ ID NO:5, or a variant of SEQ ID NO:5, wherein said fragment or mutant or variant codes for a CD34 surface marker which is identifiable by an antibody against CD34.~~

9. (Previously Presented) An isolated host cell comprising a vector according to Claim 1.

10. (Previously Presented) The isolated host cell according to claim 9, wherein said host cell is a human cell.

11. (Previously Presented) The isolated host cell according to claim 10, wherein said cell is a T-lymphocyte.

Claims 12-34 (Canceled).

35. (Currently Amended) A gene transfer vector which contains

- a) a transgene consisting of a ~~therapeutic gene or~~ suicide gene and
- b) a nucleic acid sequence coding an amino acid sequence which is identifiable by a human CD34 specific antibody, said amino acid sequence being expressed as a surface marker.

36. (Previously Presented) The vector according to claim 35, wherein the vector is a retroviral vector.

37. (Previously Presented) The vector according to claim 35, further comprising a second nucleic acid sequence coding for a second surface marker.

38. (Previously Presented) An isolated host cell comprising a vector according to claim 35.

39. (Previously Presented) The isolated host cell according to claim 38, wherein said host cell is a human cell.

40. (Previously Presented) The isolated host cell according to claim 39, wherein said cell is a T-lymphocyte.